Acting Director: Mireille Rosenberg, PhD

A core resource of the CIMIT Consortium, the Office of Technology Implementation (OTI) is dedicated to maximizing the deliverable benefits derived from funded translational research projects, programs, and initiatives.

OTI provides four key services to the investigators, institutions, and partners that make up the CIMIT Consortium community.

1. Select the projects and programs most likely to produce the maximum benefit to the soldiers, the patients, their doctors, and their families in need of advanced medical devices and technologies.
2. Design and implement individualized, targeted plans that will bring these advances into clinical practice at the fastest, safest pace possible.
3. The investigators and their institutions to create and manage their intellectual assets to maximize the value of their patent portfolio and to share equitably in the commercial success of their discoveries and inventions.
4. Create and integrate new business and investment models that will deliver these breakthroughs to all of the patients who need them at the lowest possible cost and the shortest possible time.

OTI also supports the technology transfer and licensing functions of each member institution, and actively assists in the process of transforming invention disclosures into intellectual assets, and individual patents into powerful patent portfolios. OTI collaborates with other CIMIT core services in the following ways: identify ideal candidates for public-private partnerships; seek the most appropriate sources of translational support and funding alternatives; and design cooperative relationships that will validate the safety and efficacy of the concept and accelerate the wide-spread acceptance of new standards for patient care.

Finally, OTI actively interfaces with many public and private institutions, companies, foundations, trade associations, government agencies, NGO’s, and international health providers. These relationships helps CIMIT better understand the local, regional, national, and international health care priorities, the barriers to innovation and access, and the economic and social impact of new medical technologies so that we can more strategically select and advance future projects.